Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Non-Small Cell Lung Cancer (NSCLC): Update Bulletin [November 2016]

Product Code:
596200618
Publication Date:
November 2016
Format:
PDF
Price:
£1,140

Gain new KOL insights on the latest events happening in non-small cell lung cancer (NSCLC); the approval of Merck & Co.’s Keytruda (pembrolizumab) for the first-line treatment of patients with metastatic NSCLC whose tumours have high PD-L1 expression; the presentation of results from the KEYNOTE-021 trial of Keytruda in combination with pemetrexed (Alimta; Eli Lilly) for the first-line treatment of advanced NSCLC at the European Society for Medical Oncology (ESMO) 2016 Congress; the presentation of data from the CheckMate-026 trial of Bristol-Myers Squibb’s nivolumab (Opdivo) at ESMO 2016; the FDA approval of Roche’s Tecentriq (atezolizumab) for the treatment of NSCLC that has progressed following first-line therapy.

Highlights from this event update bulletin

  • How do KOLs react to the approval of Keytruda for the first-line treatment of NSCLC and what is the likelihood that Keytruda will become standard of care in this setting?
  • How do KOLs view data from the KEYNOTE-024 study?
  • To what extent will Keytruda be used for the first-line treatment of patients whose tumours are PD-L1 positive but don’t reach the 50 percent threshold?
  • How do KOLs view the use of Keytruda in combination with pemetrexed in the first-line setting, given the KEYNOTE-021 results?
  • What does the future look like for Opdivo monotherapy in advanced NSCLC in light of the CHECKMATE-026 results?
  • Which factors do KOLs think could have influenced the negative outcome of the CHECKMATE-026 trial, even in patients with high PD-L1 expression?
  • Will there be a market for Tecentriq following its FDA approval in a highly competitive setting?

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.




customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved